Kiniksa Pharmaceuticals International (KNSA) Tax Provisions (2017 - 2026)

Kiniksa Pharmaceuticals International's Tax Provisions history runs 10 years deep, the most recent figure standing at $10.1 million for Q1 2026.

• Quarterly Tax Provisions rose 43.6% year-over-year to $10.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.0 million (up 31.7% YoY) and the FY2025 annual result came in at $10.9 million, up 55.5% from the prior year.
• Tax Provisions was $10.1 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from -$9.8 million in the prior quarter.
• Across five years, Tax Provisions topped out at $187.9 million in Q4 2022 and bottomed at -$177.4 million in Q3 2022.
• A 5-year average of $2.6 million and a median of $5.0 million in 2025 frame the typical range for Tax Provisions.
• Peak annual rise in Tax Provisions reached 70002.61% in 2022, while the deepest fall reached 150203.39% in 2022.
• Kiniksa Pharmaceuticals International's Tax Provisions stood at $187.9 million in 2022, then plunged by 94.14% to $11.0 million in 2023, then tumbled by 173.55% to -$8.1 million in 2024, then fell by 21.67% to -$9.8 million in 2025, then soared by 202.49% to $10.1 million in 2026.
• Business Quant data shows KNSA's Tax Provisions at $10.1 million in Q1 2026, -$9.8 million in Q4 2025, and $8.7 million in Q3 2025.